Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors

NCT01762410 | Suspended Phase 1

• 1 other identifier: P7170/70/11
• Study Type: interventional
• Target: 60
• Locations: 2 countries
• Sites: 4

Brief Summary

Clinical study of oral PI3K/mTOR inhibitor P7170 in patients with advanced refractory solid tumors. The primary objective is to determine the maximum tolerated dose and dose limiting toxicity of oral PI3K/mTOR inhibitor P7170 in patients with advanced refractory solid tumors

Conditions

Advanced Refractory Solid Tumors

Keywords

Advanced refractory solid tumors

Outcome Measures

Primary Outcomes (1)

• Maximum tolerated dose

  Patients will receive study drug on a daily basis for twenty-one days according to the dose and schedule specified for a particular cohort of therapy. Toxicities observed in Cycle 1 will be considered for dose limiting toxicity (DLT) and Maximum tolerated dose (MTD)determination.

  End of Cycle 1 (i.e. 21 Days)

Secondary Outcomes (4)

• Number of subject with adverse events

  Until disease progression or unacceptable toxicity (expected to be 4-6 months)

• Pharmacokinetic profile(Cmax,Tmax and AUC)

  Until disease progression or unacceptable toxicity (expected to be 4-6 months)

• Activity of P7170 based on selected biomarkers

  Until disease progression or unacceptable toxicity (expected to be 4-6 months)

• Objective response

  Until disease progression or unacceptable toxicity (expected to be 4-6 months)

Study Arms (1)

P7170

EXPERIMENTAL

Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design.

Drug: P7170

Interventions

P7170 DRUG

Patients will receive study drug on a daily basis for twenty-one days according to the dose and schedule specified for a particular cohort of therapy. This 21 day administration will define a treatment cycle. Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, death or withdrawal from the protocol as specified.

P7170

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients having histologically and/or cytologically confirmed non-haematological malignancy that is metastatic or unresectable and for which standard curative/palliative treatment does not exist or is no longer effective or is not tolerated by patient.
• Patients of either sex, of all races and ethnic groups, and more than 18 years of age.
• ECOG (Eastern Cooperative Oncology Group) performance status less than 2.
• Patients with life expectancy of at least 4 months.
• Patients with measurable or evaluable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.
• Patients must have adequate organ and marrow function as defined below:
• Absolute neutrophil count more than equal to 1500/cmm
• Platelets more than equal 100,000/cmm
• Total bilirubin within normal limits of the institution.
• AST/ALT less than equal 2.5 X institutional upper limit of normal (ULN) or less than equal 5 X institutional upper limit of normal (ULN) in the presence of liver metastases
• Creatinine less than equal 1.5 X institutional upper limit of normal (ULN)
• Women of childbearing potential and men willing to agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the duration of study participation and for at least 4 weeks after withdrawal from the study, unless they are surgically sterilised.
• Ability to understand and the willingness to provide a written informed consent document.

You may not qualify if:

• Patients who have received any prior chemotherapy, radiotherapy, biologic/targeted anti-cancer therapy or surgery within 4 weeks (3 months for monoclonal antibodies, radioactive monoclonal antibodies or any radio- or toxin- immunoconjugates) before study drug administration and have not recovered (to \< Grade 1) from the toxic effects from any prior therapy.
• Patients having received any other investigational agents within 4 weeks prior to the date of enrolment and have not recovered completely (to \< Grade 1) from the side effects of the earlier investigational agent.
• Patients with known brain metastases (except for patients who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for two months prior to first dose of study drug.)
• Patients with a history of myocardial infarction or uncontrolled cardiac dysfunction during the previous 6 months.
• Patients with diabetes mellitus requiring insulin therapy at screening or patients with clinically significant diabetic complications, such as neuropathy, retinopathy, peripheral vascular disease or nephropathy.
• Clinically significant medical condition of malabsorption, inflammatory bowel disease, or chronic diarrheal condition that might affect the absorption of the investigational agent.
• Patients on chronic anticoagulation treatment. Prophylactic anticoagulation with low-molecular heparin is allowed.
• Patients with inter-current illness including, but not limited to ongoing or clinically significant active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Patients with a known history of allergic reaction to any other medication considered to be clinically significant by the investigator.
• Women who are pregnant or nursing.
• Patients with immune deficiency and at increased risk of lethal infections, for example, known h/o HIV, HBV or HCV.

Sponsors & Collaborators

• Piramal Enterprises Limited: lead

Study Sites (4)

USC Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

Location

Medanta Duke Research Institute (MDRI)

Gurgaon, Haryana, 122001, India

Location

Central India Cancer Research Institute

Nagpur, Maharashtra, India

Location

Meenakshi Mission Hospital & Research Centre

Madurai, Tamil Nadu, 625107, India

Location

MeSH Terms

Interventions

P7170 compound

Study Officials

• Anthony El-Khoueiry, MD

  University of Southern California

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 20, 2012
• First Posted: January 7, 2013
• Study Start: September 1, 2012
• Primary Completion: November 1, 2015
• Study Completion: March 1, 2016
• Last Updated: September 29, 2014

Record last verified: 2014-09

Locations

US (1); IN (3)